Treatment of hyperammonemia in liver failure

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 17, Issue 1, 2014, Pages 105-110

  Jover Cobos, Maria ^a   Khetan, Varun ^a   Jalan, Rajiv ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Hepatic encephalopathy; Hyperammonia; Liver failure; Ornithine phenylacetate; Rifaximin

Indexed keywords

ALBUMIN; ANTIBIOTIC AGENT; ASPARTIC ACID; BRANCHED CHAIN AMINO ACID; CARNITINE; DISACCHARIDE; GLYCEROL PHENYLBUTYRATE; ORNITHINE; PREBIOTIC AGENT; PROBIOTIC AGENT;

AMMONIA FORMATION; CLINICAL TRIAL (TOPIC); CONTROLLED CLINICAL TRIAL (TOPIC); HEMODIAFILTRATION; HEMODIALYSIS; HEPATIC ENCEPHALOPATHY; HUMAN; HYPERAMMONEMIA; NONHUMAN; NUTRITION; PORTOCAVAL SHUNT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

AMMONIA; BRAIN; GLYCEROL; HEPATIC ENCEPHALOPATHY; HUMANS; HYPERAMMONEMIA; LACTULOSE; PHENYLBUTYRATES; PROBIOTICS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RIFAMYCINS;

EID: 84890980584     PISSN: 13631950     EISSN: 14736519     Source Type: Journal    
DOI: 10.1097/MCO.0000000000000012     Document Type: Review

References (24)

1. Felipo V, Butterworth RF. Neurobiology of ammonia. Prog Neurobiol 2002; 67:259-279; PubMed PMID: 12207972. (Pubitemid 35229984)
2. Bianchi G, Giovagnoli M, Sasdelli AS, Marchesini G. Hepatic encephalopathy and health-related quality of life. Clin Liver Dis 2012; 16:159-170; PubMed PMID: 22321471.
3. Bersagliere A, Raduazzo ID, Nardi M, et al. Induced hyperammonemia may compromise the ability to generate restful sleep in patients with cirrhosis. Hepatology 2012; 55:869-878; PubMed PMID: 21994139.
4. Ferenci P, Lockwood A, Mullen K, et al. Hepatic encephalopathy: definition, nomenclature, diagnosis, and quantification - final report of the working party at the 11th World Congresses of Gastroenterology, Vienna. Hepatology 2002; 35:716-721; PubMed PMID: 11870389. Epub 2002/03/01. eng. (Pubitemid 34183979)
5. Gluud LL, Dam G, Borre M, et al. Lactulose, rifaximin or branched chain amino acids for hepatic encephalopathy: what is the evidence? Metab Brain Dis 2013; 28:221-225; PubMed PMID: 23275147.
6. Ferenci P. Hepatic Encephalopathy in Adults: Treatment. ©UptoDate. http:// www.uptodate.com/contents/hepatic-encephalopathy-in-adults-treatment. [Accessed on 21 August 2013]. This is a website describing up to date clinical studies of hyperammonia.
7. Wu D, Wu SM, Lu J, et al. Rifaximin versus nonabsorbable disaccharides for the treatment of hepatic encephalopathy: a meta-analysis. Gastroenterol Res Pract 2013; 2013:236963; PubMed PMID: 23653636. Pubmed Central PMCID: 3638683.
8. Sharma BC, Sharma P, Lunia MK, et al. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy. Am J Gastroenterol 2013; 108:1458-1463; PubMed PMID: 23877348.
9. Rose CF. Ammonia-lowering strategies for the treatment of hepatic encephalopathy. Clin Pharmacol Therap 2012; 92:321-331; PubMed PMID: 22871998. Epub 2012/08/09. eng. An interesting review of molecular mechanisms that decrease amonia in hepatic encephalopathy in animal models and patients as of 2012.
10. Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010; 362:1071-1081; PubMed PMID: 20335583. Epub 2010/03/26. eng.
11. Agrawal A, Sharma BC, Sharma P, Sarin SK. Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open-label, randomized controlled trial of lactulose, probiotics, and no therapy. Am J Gastroenterol 2012; 107:1043-1050; PubMed PMID: 22710579.
12. Merli M, Giusto M, Lucidi C, et al. Muscle depletion increases the risk of overt and minimal hepatic encephalopathy: results of a prospective study. Metab Brain Dis 2012; 28:281-284; PubMed PMID: 23224378. Epub 2012/12/12. Eng.
13. Kato A, Tanaka H, Kawaguchi T, et al. Nutritional management contributes to improvement in minimal hepatic encephalopathy and quality of life in patients with liver cirrhosis: a preliminary, prospective, open-label study. Hepatol Res 2013; 43:452-458; PubMed PMID: 22994429. This article demonstates the importance of the managing malnutrition common in patients with hepatic encephalopathy.
14. Dam G, Keiding S, Munk OL, et al. Branched-chain amino acids increase arterial blood ammonia in spite of enhanced intrinsic muscle ammonia metabolism in patients with cirrhosis and healthy subjects. Am J Physiol Gastrointest Liver Physiol 2011; 301:G269-G277; PubMed PMID: 21636533.
15. Bai M, Yang Z, Qi X, et al. l-ornithine-l-aspartate for hepatic encephalopathy in patients with cirrhosis: a meta-analysis of randomized controlled trials. J Gastroenterol Hepatol 2013; 28:783-792; PubMed PMID: 23425108.
16. Acharya SK, Bhatia V, Sreenivas V, et al. Efficacy of L-ornithine L-aspartate in acute liver failure: a double-blind, randomized, placebo-controlled study. Gastroenterology 2009; 136:2159-2168; PubMed PMID: 19505424. Epub 2009/06/10. eng.
17. Malaguarnera M, Bella R, Vacante M, et al. Acetyl-L-carnitine reduces depression and improves quality of life in patients with minimal hepatic encephalopathy. Scand J Gastroenterol 2011; 46:750-759; PubMed PMID: 21443422.
18. Ventura-Cots M, Arranz JA, Simon-Talero M, et al. Safety of ornithine phenylacetate in cirrhotic decompensated patients: an open-label, doseescalating, single-cohort study. J Clin Gastroenterol 2013; 47:881-887; PubMed PMID: 23751856. The authors show the effective use of ornithinephenylacetate as a well tolerated and efficacious therapy for the first time in patients with cirrhosis and gastrointestinal bleeding.
19. Rockey DC, Vierling JM, Mantry P, et al. Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy. Hepatology 2013; 56:248A; PubMed PMID: 23847109. This article describes the improvement in hepatic encephalopathy episodes in patients with a new drug (HPN-100) in the treatment of hepatic encephalopathy. The underlying mechanism has to be studied in more detail.
20. Laleman W, Simon-Talero M, Maleux G, et al. Embolization of large spontaneous portosystemic shunts for refractory hepatic encephalopathy: a multicenter survey on safety and efficacy. Hepatology 2013; 57:2448- 2457; PubMed PMID: 23401201. Embolization of these shunts has been shown to be effective immediately (within 100 days) in resolving hepatic encephalopathy. However, this treatment only works if there is residual liver function. It is less effective, and can be deleterious in patients with end-stage liver disease.
21. Simon-Talero M, Garcia-Martinez R, Torrens M, et al. Effects of intravenous albumin in patients with cirrhosis and episodic hepatic encephalopathy: a randomized double-blind study. J Hepatol 2013; 59: 1184-1192. The importance of this article is that albumin administration helps to prolong survival of patients with hepatic encephalopathy but did not prevent recurrence of hepatic encephalopathy.
22. Cordoba J, Blei AT, Mujais S. Determinants of ammonia clearance by hemodialysis. Artif Organs 1996; 20:800-803; PubMed PMID:8828772. (Pubitemid 26254774)
23. Sen S, Felldin M, Steiner C, et al. Albumin dialysis and Molecular Adsorbents Recirculating System (MARS) for acute Wilson's disease. Liver Transpl 2002; 8:962-967; PubMed PMID: 12360442. Epub 2002/10/03.eng. (Pubitemid 35154030)
24. Karvellas CJ, Gibney N, Kutsogiannis D, et al. Bench-to-bedside review: current evidence for extracorporeal albumin dialysis systems in liver failure. Crit Care 2007; 11:215; PubMed PMID: 17567927. PubmedCentral PMCID: 2206413.